蛋白酪氨酸磷酸酶调控破骨细胞作用机制的研究进展

doi:10.13701/j.cnki.kqyxyj.2021.09.002

口腔医学研究 ›› 2021, Vol. 37 ›› Issue (9): 780-782.DOI: 10.13701/j.cnki.kqyxyj.2021.09.002

蛋白酪氨酸磷酸酶调控破骨细胞作用机制的研究进展

张帆, 姜欢^*

吉林大学口腔医院正畸科吉林长春 130021

收稿日期:2020-06-02 出版日期:2021-09-28 发布日期:2021-09-16
通讯作者: *姜欢,E-mail : jianghuan@jlu.edu.cn
作者简介:张帆(1998~),吉林人,女,本科在读,研究方向:口腔正畸学。
基金资助:
国家自然科学基金(编号:81870795)国家自然科学基金青年基金(编号:81600898)吉林省财政厅课题(编号:JCSZ2019378-19)

Research Progress on Mechanism of Protein Tyrosine Phosphatase Regulating Osteoclast

ZHANG Fan, JIANG Huan^*

Department of Orthodontics, Hospital of Stomatology, Jilin University, Changchun 130021, China

Received:2020-06-02 Online:2021-09-28 Published:2021-09-16

摘要/Abstract

摘要： 破骨细胞蛋白酪氨酸磷酸酶(osteoclastic protein-tyrosine phosphatase,PTP-oc)是一种特异性表达于破骨细胞和破骨细胞前体细胞中的蛋白质酪氨酸磷酸酶,通过多种机制参与调控破骨细胞的生物学行为。本文从PTP-oc调节破骨细胞活性、分化、粘附3个方面,对其作用机制进行综述,为深入研究PTP-oc的作用提供参考,也为以PTP-oc为靶点防治正畸牙移动过程中牙根吸收提供一定的依据。

关键词: 蛋白酪氨酸磷酸酶, 破骨细胞, 作用机制

Abstract: Osteoclastic protein-tyrosine phosphatase (PTP-oc) is a protein tyrosine phosphatase specifically expressed in osteoclasts and osteoclast precursor cells, which is involved in the regulation of biological behavior of osteoclasts through a variety of mechanisms. In this paper, the mechanism of PTP-oc in regulating activity, differentiation, and adhesion of osteoclast was summarized, which provides reference for further study on the role of PTP-oc, and also provides some evidence for the prevention and treatment of root resorption in the process of orthodontics tooth movement with PTP-oc as the target.

Key words: protein tyrosine phosphatase, osteoclasts, mechanism of action

张帆, 姜欢. 蛋白酪氨酸磷酸酶调控破骨细胞作用机制的研究进展[J]. 口腔医学研究, 2021, 37(9): 780-782.

ZHANG Fan, JIANG Huan. Research Progress on Mechanism of Protein Tyrosine Phosphatase Regulating Osteoclast[J]. Journal of Oral Science Research, 2021, 37(9): 780-782.

参考文献

[1] Ruddraraju KV, Zhang ZY. Covalent inhibition of protein tyrosine phosphatases [J]. Mol Biosyst, 2017, 13(7):1257-1279.
[2] Lountos GT, Raran-Kurussi S, Zhao BM, et al. High-resolution crystal structures of the D1 and D2 domains of protein tyrosine phosphatase epsilon for structure-based drug design [J]. Acta Crystallogr D Struct Biol, 2018, 74(10):1015-1026.
[3] Frankson R, Yu ZH, Bai Y, et al. Therapeutic targeting of oncogenic tyrosine phosphatases [J]. Cancer Res, 2017, 77(21):5701-5705.
[4] Sharma Y, Bashir S, Bhardwaj P, et al. Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders [J]. Immunol Res, 2016, 64(4):804-819.
[5] Gurzov EN, Stanley WJ, Brodnicki TC, et al. Protein tyrosine phosphatases: molecular switches in metabolism and diabetes [J]. Trends Endocrinol Metab, 2015, 26(1):30-39.
[6] Shalev M, Elson A. The roles of protein tyrosine phosphatases in bone-resorbing osteoclasts [J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(1):114-123.
[7] Lau KW, Sheng MH. A novel miR17/protein tyrosine phosphatase-oc/EphA4 regulatory axis of osteoclast activity [J]. Arch Biochem Biophys, 2018, 650: 30-38.
[8] Wu LW, Baylink DJ, Lau KH. Molecular cloning and expression of a unique rabbit osteoclastic phosphotyrosyl phosphatase [J]. Biochem J,1996, 316(Pt 2): 515-523.
[9] Roth L, Wakim J, Wasserman E, et al. Phosphorylation of the phosphatase PTPROt at Tyr399 is a molecular switch that controls osteoclast activity and bone mass in vivo [J]. Sci Signal, 2019, 12(563):eaau0240.
[10] Amoui M, Baylink DJ, Tillman JB, et al. Expression of a structurally unique osteoclastic protein-tyrosine phosphatase is driven by an alternative intronic, cell-type-specific promoter [J]. J Biol Chem, 2003, 278(45): 44273-44280.
[11] Yang JH, Amoui M, Lau KH. Targeted deletion of the osteoclast protein-tyrosine phosphatase (PTP-oc) promoter prevents RANKL-mediated osteoclastic differentiation of RAW264.7cells [J] . FEBS Lett, 2007, 581(13): 2503-2508.
[12] Lau KH, Wu LW, Sheng MH, et al. A unique osteoclastic transmembrane protein-tyrosine phosphatase is a potential positive regulator of the c-src proteintyrosine kinase activity, a mediator of osteoclast activity [J]. J Cell Biochem, 2006, 97(5): 940-955.
[13] Tharmalingam S, Hampson DR. The Calcium-sensing receptor and integrins in cellular differentiation and migration [J]. Front Physiol, 2016, 7:190.
[14] Rucci N, Teti A. The "love-hate" relationship between osteoclasts and bone matrix [J]. Matrix Biol, 2016, 52-54:176-190.
[15] Huntley R, Jensen E, Gopalakrishnan R. Bone morphogenetic proteins: Their role in regulating osteoclast differentiation [J]. Bone Rep, 2019, 10:100207.
[16] Lau KH, Stiffel V, Amoui M. An osteoclastic protein-tyrosine phosphatase regulates the β3-integrin, syk, and shp1 signaling through respective src-dependent phosphorylation in osteoclasts [J]. Am J Physiol Cell Physiol, 2012, 302(11): C1676-C1686.
[17] Chatterjee D, D'Souza A, Zhang Y. Interaction analyses of 14-3-3ζ, Dok1, and phosphorylated integrin β cytoplasmic tails reveal a bi-molecular switch in integrin regulation [J]. J Mol Biol, 2018, 430(21):4419-4430.
[18] Amoui M, Sheng MH, Chen ST, et al. A transmembrane osteoclastic protein-tyrosine phosphatase regulates osteoclast activity in part by promoting osteoclast survival through c-Src-dependent activation of NFkappa B and JNK2 [J]. Arch Biochem Biophys, 2007, 463(1): 47-59.
[19] Kang X, Kim J, Deng M, et al. Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors[J]. Cell Cycle, 2016, 15(1):25-40.
[20] Stiffel V, Amoui M, Sheng MH, et al. EphA4 receptor is a novel negative regulator of osteoclast activity [J]. Bone Miner Res, 2014, 29(4):804-819.
[21] Lau KH, Amoui M, Stiffel V, et al. An osteoclastic transmembrane protein-tyrosine phosphatase enhances osteoclast activity in part by dephosphorylating Eph A4 in osteoclasts [J]. J Cell Biochem, 2015, 116(8):1785-1796.
[22] Bai X, Hua S, Zhang J, et al. The microRNA family both in normal development and in different diseases: The miR-17-92 cluster [J]. Biomed Res Int, 2019, 2019:9450240.
[23] Cui C, Cui Y, Fu Y, et al. Microarray analysis reveals gene and microRNA signatures in diabetic kidney disease [J]. Mol Med Rep, 2018, 17(2):2161-2168.
[24] Ji X, Chen X, Yu X. MicroRNAs in osteoclastogenesis and function: potential therapeutic targets for osteoporosis [J]. Int J Mol Sci, 2016, 17(3):349.
[25] Lau KW, Stiffel VM, Rundle CH, et al. Conditional disruption of miR17~92 in osteoclasts led to activation of osteoclasts and loss of trabecular bone in part through suppression of the miR17-mediated downregulation of protein-tyrosine phosphatase-oc in mice [J]. JBMR Plus, 2017, 1(2):73-85.
[26] Reddy RH, Kim H, Cha S, et al. Structure-based virtual screening of protein tyrosine phosphatase inhibitors: significance, challenges, and solutions [J]. J Microbiol Biotechnol, 2017, 27(5):878-895.

蛋白酪氨酸磷酸酶调控破骨细胞作用机制的研究进展

Research Progress on Mechanism of Protein Tyrosine Phosphatase Regulating Osteoclast

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	金挺, 崔磊华, 王惠宁, 侯玉帛. PMX205对致敏毒素C5a诱导RAW264.7向破骨细胞分化的影响[J]. 口腔医学研究, 2021, 37(7): 637-640.
[2]	梁向阳, 李春年. 雷尼酸锶对实验性牙周炎大鼠牙槽骨改建的影响[J]. 口腔医学研究, 2021, 37(4): 310-313.
[3]	苏娟娟, 朱永翠, 张文玲. 连翘苷对牙周炎大鼠p38 MAPK/c-Fos信号通路及破骨细胞活化的影响[J]. 口腔医学研究, 2021, 37(1): 33-38.
[4]	何梦婷, 白丁. 牙囊在牙萌出的作用及其调控机制研究进展[J]. 口腔医学研究, 2020, 36(2): 107-110.
[5]	张诗晨, 韩冰. 二甲双胍治疗头颈部鳞状细胞癌机制的研究进展[J]. 口腔医学研究, 2020, 36(12): 1091-1094.
[6]	胡英英, 哈珊珊, 朱宁静, 宋亚玲, 汪昌宁. 雌激素作用下罗格列酮对RAW264.7向破骨细胞分化的影响[J]. 口腔医学研究, 2019, 35(5): 502-506.
[7]	阮国宪, 高丽卿, 邓立. 周期性压应力诱导髁突软骨细胞分泌促破骨因子的研究[J]. 口腔医学研究, 2019, 35(4): 372-376.
[8]	冯丽华, 夏海斌. 抑瘤素M调控骨稳态的研究进展[J]. 口腔医学研究, 2019, 35(11): 1026-1029.
[9]	史东梅, 徐慧君, 左美娜, 仉红, 张咪, 吴赛璇, 董明, 牛卫东. 粪肠球菌脂磷壁酸作用的炎症微环境下磷脂酶 Cγ表达研究[J]. 口腔医学研究, 2019, 35(11): 1084-1088.
[10]	王佳, 张文静, 韩祥祯, 周琦琪, 何惠宇. 巨噬细胞集落刺激因子过表达对信号通路中破骨相关因子的影响[J]. 口腔医学研究, 2019, 35(11): 1089-1093.
[11]	陈雅文,王海丞,董伟杰. A结构域阳性纤维连接蛋白促进破骨细胞形成及根尖囊肿骨质破坏[J]. 口腔医学研究, 2018, 34(9): 952-955.
[12]	龙甜, 程志刚. 含锶/锌钙磷涂层对RAW264.7破骨细胞体外影响的研究[J]. 口腔医学研究, 2018, 34(8): 910-912.
[13]	孙宾, 孙宏晨. 维甲酸抗肿瘤活性及其作用机制的研究进展[J]. 口腔医学研究, 2018, 34(4): 356-358.
[14]	蒋星宇, 张玉峰, 杨璐, 孙晋虎, 黎婷. 三七总皂苷在兔牙齿移动过程中对牙周组织中破骨细胞及BMP-2表达的影响[J]. 口腔医学研究, 2018, 34(4): 442-447.
[15]	唐小莹, 龙杨, 袁小平. Adrb2激动剂、拮抗剂对大鼠牙移动中牙槽骨微结构改建的影响研究[J]. 口腔医学研究, 2018, 34(11): 1217-1222.